Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2017 Financial Results
SAN DIEGO, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the …